Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated,advanced non-small cell lung cancer  

作　　者：Hideharu Kimura Tomoyuki Araya Taro Yoneda Hiroki Shirasaki Koji Kurokawa Tamami Sakai Hayato Koba Yuichi Tambo Shingo Nishikawa Takashi Sone Kazuo Kasahara 

机构地区：[1]Respiratory Medicine,Kanazawa University Hospital,Takara-machi 13-1,Kanazawa,Ishikawa 920-8641,Japan [2]Respiratory Medicine,National Hospital Organization Kanazawa Medical Center,Kanazawa,Ishikawa 920-8650,Japan [3]Respiratory Medicine,Komatsu Municipal Hospital,Komatsu,Ishikawa 923-8560,Japan [4]Respiratory Medicine,Fukui-ken Saiseikai Hospital,Fukui,Fukui 918-8503,Japan [5]Respiratory Medicine,Ishikawa Prefectural Central Hospital,Kanazawa,Ishikawa 920-8530,Japan [6]Internal Medicine,Keiju Medical Center,Nanao,Ishikawa 926-8605,Japan [7]Regional Respiratory Symptomatology,Kanazawa University Graduate School of Medical Science,Kanazawa,Ishikawa 920-8641,Japan

出　　处：《Cancer Communications》2019年第1期665-669,共5页癌症通讯（英文）

摘　　要：Dear Editor,Nivolumab,an inhibitor of programmed cell death 1(PD-1),is an immune checkpoint inhibitor(ICI)that enhances T cell functions by preventing negative regulation of cancer immunity,and it has shown clinically significant efficacy and tolerability in various types of cancer.Based on the results of randomized phase III trials comparing nivolumab with docetaxel[1,2],nivolumab is now used in clinical practice for patients with previously treated advanced non-small cell lung cancer(NSCLC).Fur-thermore,the most recent Japan Lung Cancer Society guidelines include nivolumab monotherapy in the sys-temic treatment strategy for previously treated,locally advanced or metastatic NSCLC[3].However,ICIs induce characteristic immune-related adverse events(irAEs),which are not seen with conventional cytotoxic agents or molecular targeted agents.IrAEs can occur in any organ system,most typically the skin,lung,and gastrointesti-nal,hepatic,and endocrine systems.

关 键 词：nivolumab PATIENTS LUNG 

分 类 号：R73[医药卫生—肿瘤]